Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA January 25, 2023 Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies On track to achieve 2022 financial guidance Webcast today, August 9, 2022 , at
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels Fesomersen, a novel Factor XI antisense inhibitor designed to
Ionis to hold second quarter 2022 financial results webcast
Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 27, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, August 9 th at 11:30 a.m. Eastern Time to discuss its second quarter financial
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S. , it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be the first treatment to target a genetic cause of ALS 12-month data included in the filing show
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Pelacarsen is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease There are currently no approved pharmacological therapies to effectively lower Lp(a), which cannot be effectively